In a survey of U.S. adults with diabetes, about 13% who were prescribed medication said they did not take it as prescribed, and about 24% said they asked their doctors for a lower-cost medication.
While the meta-analysis also found durable reductions in macrovascular complications and mortality with sodium-glucose cotransporter-2 (SGLT-2) inhibitors versus placebo, there were insufficient data comparing the drug class to other
An online survey of U.S. adults in mid-2020, most of whom were White women, found that those with diabetes were less likely to report resilience and more likely to experience depression than adults without diabetes.
They pointed out that almost 50% of patients with diabetes have severe periodontitis and that their findings “highlight the potential to improve metabolic control and possibly diabetes outcomes by addressing poor
The industry-funded PIONEER 3 trial randomized adults whose type 2 diabetes was uncontrolled with metformin, with or without sulfonylurea, to receive either oral sitagliptin (100 mg/d) or oral semaglutide (3, 7, or 14 mg/d).
This study highlights the importance and raises awareness of the risks of cholecystitis with dipeptidyl peptidase-4 inhibitors for physicians and should encourage researchers to make them predefined safety endpoints,” said
Our findings highlight poorly controlled diabetes and its cardiovascular complications as ideal targets for interventions to prevent cognitive impairment or arrest its progression to dementia—conditions for which no curative treatment
The authors of a small Italian study of hospitalized COVID-19 patients speculated that reversible transient factors, such as inflammation-induced insulin resistance, may cause the hyperglycemia that occurs in some patients with and without diabetes
The results of a retrospective study of U.S. data in patients with both diabetes and end-stage kidney disease (ESKD) indicate that current glycemic monitoring and treatment in this population are suboptimal, the authors said.
A retrospective study of veterans with diabetes found that those who started statin therapy were more likely to meet criteria for diabetes progression, such as initiation of insulin or an additional antihyperglycemic drug class, over time.